GE Healthcare has secured clearance from the European Medicines Agency for additional imaging modalities for its Rapiscan stress contrast agent.
Rapiscan is already cleared for SPECT myocardial perfusion imaging in adults. The expanded clearance now covers MRI, CT, and PET.
Rapiscan helps clinicians diagnose coronary artery disease, and it does not require weight and age-based modifications or an infusion pump, GE said.
